Boehringer Ingelheim

Company snapshot

Boehringer Ingelheim maintains 193 tracked programs across Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstructive, Asthma, Chronic Kidney Disease, Carcinoma, Non-Small-Cell Lung, Hypertension, Bronchiectasis, Hepatitis C, Atrial Fibrillation, Schizophrenia. Momentum score: 24/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical tr

• 193 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Boehringer Ingelheim. Not investment advice.

• approval Jun 11, 2026

  CHMP backs nerandomilast for IPF and PPF in EU

• What is Boehringer Ingelheim?

  Boehringer Ingelheim is a pharma organization headquartered in Ingelheim am Rhein, DE. Primary therapeutic focus areas include Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity, Pulmonary Disease, Chronic Obstructive, Asthma. NovaPharmaNews links 193 clinical program(s),

• Is Boehringer Ingelheim publicly traded?

  Boehringer Ingelheim appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Boehringer Ingelheim develop or market?

  We link 79 drug profile(s) where Boehringer Ingelheim is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/boehringer-ingelheim-international-gmbh#company-drugs.

• What are the latest developments for Boehringer Ingelheim?

  In the last 12 months our linked public records show 193 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Boehringer Ingelheim focus on?

  Boehringer Ingelheim focuses on Diabetes Mellitus, Type 2, Pharmacokinetic trial, Obesity based on our analysis of their pipeline programs and drug development activities.